Multi-billion-dollar acquisition in the U.S.: Bayer’s risky bet on ophthalmology:
Amid the glyphosate dispute, corporate restructuring, and high debt ...
manager-magazin.de/unternehmen/pharma/bayer-milliardeninvestition-in-augenheilkunde-unternehmen-perfuse-therapeutics-nach-eylea-patentverlust-a-6a42f562-d88d-4a63-a1ff-9d4cff26fe25
Story Details
| Last Updated | |
| Total Articles | 1 |
Main Topics
agreement between two parties that a stake will be paid by the loser to the winner according to the outcome of an external event or fact
Similar to This
Previous
Bayer is pursuing a clear plan: Bayer has already made numerous attempts to mitigate the legal risks surrounding glyphosate. So far, without success ...
faz.net/aktuell/wirtschaft/unternehmen/bayer-verfolgt-einen-klaren-plan-200825315.html
Bayer subsidiary: Monsanto reaches billion-dollar settlement in glyphosate dispute
zdfheute.de/wirtschaft/unternehmen/bayer-monsanto-glyphosat-roundup-vergleich-100.html
Key FactsBillion-Dollar Settlement Ends Glyphosate Lawsuits
Feb 17, 2026 · Reading time: ~45 sec.
Summary created with AI assistance · Source: stuttgarter-nachrichten.de
Summary created with AI assistance · Source: stuttgarter-nachrichten.de
- Monsanto, a Bayer subsidiary, finalized a class-action settlement in the US regarding glyphosate-related lawsuits.
- The settlement includes payments capped at $7.25 billion to be disbursed over a 21-year span.
- This long-term deal provides Monsanto with greater financial predictability for both existing and future claims.
- Bayer clarified that the agreement does not admit liability and denies the allegations against glyphosate.
The agreement on the class action settlement creates 'a clear path out of the uncertainties created by the legal disputes'— Bayer CEO Bill Anderson explains the significance of the settlement agreement.
Next